Compare Enovix Corporation (ENVX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Stryker Corporation — how do they compare? Enovix Corporation trades at $4.78 (market cap $1.06B), while Stryker Corporation trades at $345.5 (market cap $133.54B). The key difference: Stryker Corporation is far larger — about 126× Enovix Corporation's market cap, and Stryker Corporation pays a 1.01% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | SYK | |
|---|---|---|
Market Cap | $1.06B | $133.54B |
Sector | Technology | Technology |
52-Week High | $13.19 | $394.34 |
52-Week Low | $3.68 | $282.58 |
Enterprise Value | $1.07B | $145.01B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX is trading at $4.825, up 3.99% with strong analyst support (75% buy ratings) and a $12.38 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics, with recent earnings beats and strategic leadership appointments driving optimism. Revenue growth remains modest at $31.82M for 2025, but significant cash burn and negative margins highlight execution risks as the company scales battery production.
The outlook balances high growth potential in advanced battery technology against substantial financial losses. Investment opportunity lies in market leadership in silicon-anode batteries and recent operational improvements, while risks include persistent cash burn and competitive pressures in the evolving energy storage sector.
Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.
Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
